Metoclopramide Hcl
Brand names: Metoclopramide Hcl, Reglan, Gimoti
At a glance
- Medicare prescriptions, 2024
- 616,067
- Medicare drug cost
- $6.9M
- Average cost per prescription
- $11.28
- Clinicians who prescribed it
- 23,687
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
From the FDA-approved prescribing information (label dated February 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: TARDIVE DYSKINESIA Metoclopramide, including GIMOTI, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including GIMOTI, the risk of developing TD increases with duration of treatment and total cumulative dosage. GIMOTI is contraindicated in patients with a history of TD. Use GIMOTI for the shortest duration of treatment and periodically reassess the need for continued treatment. Immediately discontinue GIMOTI in patients who develop signs or symptoms of TD. Avoid a total duration of treatment with metoclopramide products, including GIMOTI, for longer than 12 weeks. If longer-term use is unavoidable, routinely monitor for signs and symptoms of TD. WARNING: TARDIVE DYSKINESIA See full prescribing information for complete boxed warning. Metoclopramide, including GIMOTI, can cause tardive dyskinesia…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 24.9%
- Internal Medicine 21.4%
- Nurse Practitioners 15.9%
- Gastroenterology 15.9%
- Physician Assistants 5.5%
- General Practice 2.9%
- General Surgery 2.0%
- Geriatric Medicine 1.7%
- Emergency Medicine 1.5%
- Pain Medicine 1.0%
- Nephrology (Kidney) 0.9%
- Pulmonology 0.8%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 9% from 2019 to 2024.
Biggest change by state since 2019
- Utah +15%
- Nevada +7%
- Oregon +5%
- Puerto Rico +3%
- Florida +3%
- Maine (smallest change) −21%
- Tennessee (smallest change) −17%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $254,743 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Evoke Pharma, Inc. $254,743
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.